RIGL
Rigel Pharmaceuticals Inc.
$29.17
+$0.16(+0.55%)
54
Overall
80
Value
36
Tech
47
Quality
Market Cap
$523.61M
Volume
441.63K
52W Range
$18.14 - $52.24
Target Price
$53.20
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $20.4M | $4.5M | $44.5M | $59.3M | $108.6M | $149.2M | $120.2M | $116.9M | $179.3M | $294.3M | ||
| Total Revenue | $20.4M | $4.5M | $44.5M | $59.3M | $108.6M | $149.2M | $120.2M | $116.9M | $179.3M | $294.3M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $-287.0K | $906.0K | $895.0K | $1.1M | $1.7M | $7.1M | $18.6M | $19.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $20.4M | $4.5M | $44.2M | $58.4M | $107.7M | $148.2M | $118.5M | $109.8M | $160.6M | $274.7M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $84.4M | $84.1M | $116.9M | $127.5M | $136.7M | $157.1M | $172.7M | $130.3M | $136.4M | $149.2M | ||
| Research & Development | $63.4M | $46.3M | $46.9M | $52.9M | $60.1M | $65.2M | $60.3M | $24.5M | $23.4M | $33.3M | ||
| Research Expense | $63.4M | $46.3M | $46.9M | $52.9M | $60.1M | $65.2M | $60.3M | $24.5M | $23.4M | $33.3M | ||
| Selling, General & Administrative | $20.9M | $37.8M | $70.0M | $74.6M | $76.6M | $91.9M | $112.5M | $105.7M | $113.1M | $115.9M | ||
| Selling & Marketing Expenses | -- | $37.8M | $70.0M | -- | -- | $2.3M | $2.7M | $3.1M | $2.1M | -- | ||
| General & Administrative Expenses | $20.9M | $-6.9M | $-6.0M | $74.6M | $76.6M | $91.9M | $112.5M | $105.7M | $113.1M | $115.9M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | $2.3M | $2.7M | -- | -- | -- | ||
| Salaries & Wages | $-7.8M | $-6.0M | $-7.7M | -- | -- | $400.0K | $12.4M | -- | -- | -- | ||
| Depreciation & Amortization | $-941.0K | $-465.0K | $-594.0K | $683.0K | $706.0K | $1.2M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-941.0K | $-465.0K | $-594.0K | $683.0K | $706.0K | $1.2M | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | $100.0K | $1.1M | $2.4M | -- | ||
| Other Operating Expenses | $-957.0K | $-527.0K | $-419.0K | $-509.0K | $-543.0K | $-285.0K | $-240.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-64.0M | $-79.6M | $-72.7M | $-69.1M | $-29.0M | $-12.5M | $-55.5M | $-20.5M | $24.2M | $125.5M | ||
| EBITDA | $-68.3M | $-77.5M | $-69.9M | $-65.9M | $-27.7M | $-11.3M | $-53.9M | $-17.0M | $28.5M | $131.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $335.0K | $1.4M | $4.9M | $3.7M | $6.9M | $7.9M | $7.3M | ||
| Intinc | $437.0K | $892.0K | $2.2M | $2.5M | $582.0K | $47.0K | $684.0K | $2.3M | $2.1M | $3.7M | ||
| Net Non-Operating Interest Income/Expense | $437.0K | $892.0K | $2.2M | $2.2M | $-771.0K | $-4.8M | $-3.0M | $-4.6M | $-5.8M | $-3.6M | ||
| Gain on Sale of Securities | $23.0K | $83.0K | $27.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-88.0K | $-732.0K | $-27.0K | $-496.0K | $-86.0K | $2.8M | $-1.3M | $700.0K | -- | -- | ||
| Other Special Charges | -- | -- | -- | -- | -- | $-2.8M | $-2.8M | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $5.8M | $-319.0K | -- | -- | -- | $3.5M | $1.3M | -- | -- | -- | ||
| Special Income Charges | $-5.8M | $319.0K | -- | -- | -- | $-3.5M | $-1.3M | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $700.0K | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-69.2M | $-78.0M | $-70.5M | $-66.6M | $-28.4M | $-12.4M | $-54.9M | $-18.2M | $26.3M | $129.1M | ||
| Pre-Tax Income | $-69.2M | $-78.0M | $-70.5M | $-66.9M | $-29.7M | $-17.3M | $-58.6M | $-25.1M | $18.4M | $121.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | $605.0K | -- | -- | $881.0K | $-245.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $-69.2M | $-78.0M | $-70.5M | $-66.9M | $-29.7M | $-17.9M | $-58.6M | $-25.1M | $17.5M | $367.0M | ||
| Net Income (Continuing Operations) | $-69.2M | $-78.0M | $-70.5M | $-66.9M | $-29.7M | $-17.9M | $-58.6M | $-25.1M | $17.5M | $367.0M | ||
| Net Income (Discontinued Operations) | $-69.2M | $-78.0M | $-70.5M | $-66.9M | $-29.7M | $-17.9M | $-58.6M | $-25.1M | $17.5M | $367.0M | ||
| Net Income (Common Stockholders) | $-69.2M | $-78.0M | $-70.5M | $-66.9M | $-29.7M | $-17.9M | $-58.6M | $-25.1M | $17.5M | $367.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-123.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $84.4M | $84.1M | $116.6M | $128.4M | $137.6M | $158.2M | $174.5M | $137.4M | $155.1M | $168.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $94.4M | $126.3M | $160.5M | $167.4M | $168.8M | $170.5M | $17.2M | $17.4M | $17.6M | $18.0M | ||
| Average Shares Outstanding (Diluted) | $94.8M | $125.8M | $167.6M | $167.4M | -- | $170.5M | $17.2M | $17.4M | $17.7M | $18.8M | ||
| Shares Outstanding | $122.3M | $147.1M | $167.2M | $168.6M | $170.0M | $171.7M | $17.4M | $17.5M | $17.9M | $18.5M | ||
| Basic EPS | -- | -- | -- | $-0.40 | $-0.18 | $-0.11 | $-3.4 | $-1.4 | $0.99 | $20.4 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-0.40 | $-0.18 | $-0.11 | $-3.4 | $-1.4 | $0.99 | $20.4 | ||
| Diluted EPS | $-0.73 | $-0.62 | $-0.44 | $-0.40 | $-0.18 | $-0.11 | $-3.4 | $-1.4 | $0.99 | $19.48 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.11 | $-3.4 | $-1.4 | $0.99 | $19.48 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | $88.0K | $732.0K | -- | $496.0K | $86.0K | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $618.0K | $7.0M | $18.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $20.9M | $-6.9M | $-6.0M | $74.6M | $76.6M | $91.9M | $112.5M | $105.7M | $113.1M | $115.9M | ||
| Provision For Gain Loss On Disposal | $618.0K | $7.0M | $18.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $20.9M | $-6.9M | $-6.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | $37.8M | $70.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $5.8M | $-319.0K | -- | -- | -- | $3.5M | $1.3M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RIGL | $29.17 | +0.6% | 441.63K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rigel Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW